ADVISORY, June 27, 2017 (GLOBE NEWSWIRE) —
Therapix Biosciences Ltd. (Nasdaq:TRPX) (“Therapix”), a specialty clinical-stage pharmaceutical company specializing in the development of cannabinoid-based drugs, will visit the Nasdaq MarketSite in Times Square.
In honor of the occasion, Dr. Elran Haber, Chief Executive Officer, will ring the Opening Bell.
Nasdaq MarketSite – 4 Times Square – 43rd & Broadway – Broadcast Studio
Wednesday, June 28, 2017 – 9:15 a.m. to 9:30 a.m. ET
Therapix Biosciences Ltd. Contact:
Tirth Patel, Vice President, Investor Relations
Fiber Line (Encompass Waterfront): 4463
Gal 3C/06C 95.05 degrees West
18 mhz Lower
DL 3811 Vertical
For multimedia features such as exclusive content, photo postings, status updates and video of bell ceremonies, please visit our Facebook page:
For photos from ceremonies and events, please visit our Instagram page:
For livestream of ceremonies and events, please visit our YouTube page:
For news tweets, please visit our Twitter page:
For exciting viral content and ceremony photos, please visit our Tumblr page:
A live stream of the Nasdaq Opening Bell will be available at:
https://new.livestream.com/nasdaq/live or http://www.nasdaq.com/about/marketsitetowervideo.asx
To obtain a hi-resolution photograph of the Market Open, please go to http://business.nasdaq.com/discover/market-bell-ceremonies and click on the market open of your choice.
About Therapix Biosciences Ltd.
Therapix Biosciences Ltd. (Nasdaq:TRPX) is a specialty clinical-stage pharmaceutical company focused on developing technologies and therapeutics based on cannabinoid pharmaceuticals. The Company’s clinical pipeline assets follow a de-risked 505(b)(2) regulatory pathway benefitting from Therapix’s unique proprietary formulations based on repurposing an FDA approved synthetic cannabinoid (dronabinol). Therapix’s lead compound, THX-TS01, is currently in Phase 2 clinical trials for Tourette’s Syndrome and the Company intends to initiate a Phase 1 clinical study of THX-ULD01 for the treatment of Mild Cognitive Impairment, for which no FDA-approved therapies currently exist. Please visit our website for more information at www.therapixbio.com.
Nasdaq (Nasdaq:NDAQ) is a leading global provider of trading, clearing, exchange technology, listing, information and public company services. Through its diverse portfolio of solutions, Nasdaq enables customers to plan, optimize and execute their business vision with confidence, using proven technologies that provide transparency and insight for navigating today’s global capital markets. As the creator of the world’s first electronic stock market, its technology powers more than 90 marketplaces in 50 countries, and 1 in 10 of the world’s securities transactions. Nasdaq is home to 3,800 total listings with a market value of $11 trillion. To learn more, visit: http://business.nasdaq.com